focus -WSS

focus

author：explore 2025-10-01 21:34:19 - browse：38

Peter Marks. -- health coverage from STAT — Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data.

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

WSS

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Thermo Fisher plant for manufacturing gene therapies to expand

Changes to biosimilar regulatory framework must prioritize patients

Why Marc Tessier

Readout LOUD podcast: possible new ALS drug, artificial wombs

Second xenotransplant done with gene

focus

focus

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Lasker Awards 2023: Winners in biomedical research

Medicare details structure of new drug price negotiation program

Biotech stock slump in 2023: awaiting the turnaround

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Duchenne breakthrough therapy leaves behind pioneering families

EMA weighs against approval for Mirati's lung cancer drug

Psychedelics group wrestles with new pharma identity

Experts study whether long Covid risk adds up with each reinfection

entertainment

Senators: Long

It's time to take a new tack for treating Alzheimer's

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Changes to biosimilar regulatory framework must prioritize patients

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Medical student insurance fails on mental health care coverage

entertainment

explore

explore

hotspot